Prosecution Insights
Prosecution Insights
33 pending office actions • 23 art units • 32 examiners • 0 of 33 (0%) have an AI response strategy ready • 38 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 10 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 10 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (6%) |
| §103 only | 9 (27%) |
| §102 only | 1 (3%) |
| Double-patenting only | 2 (6%) |
| Double-patenting + other | 2 (6%) |
| Multi-statute (no §101) | 17 (52%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HEASLEY, MEGHAN CHRISTINE | 2 | 77.2% | +33.6% |
| LOUIS, RICHARD G | 1 | 74.7% | +17.1% |
| CERIONI, DANIEL LEE | 1 | 64.7% | +28.4% |
| RAGHU, GANAPATHIRAM | 1 | 73.6% | +26.4% |
| GEBREMICHAEL, BRUK A | 1 | 22.2% | +23.7% |
| BAZARGANI, ARYA AHMADI | 1 | 75.0% | +37.5% |
| PIPIC, ALMA | 1 | 54.3% | +55.4% |
| GRASER, JENNIFER E | 1 | 76.5% | +23.6% |
| BRAUN, MADELINE E | 1 | 67.9% | +25.4% |
| GREEN, RICHARD R | 1 | 74.4% | +23.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18008605 | USE OF OXYGENATED CHOLESTEROL SULFATES FOR TREATING INFLAMMATORY CONDITIONS | RODRIGUEZ, RAYNA B | 66d overdue |
| 18271618 | METHOD OF GENE DELIVERY TO RETINAL ASTROCYTES | BRETZ, COREY LANE | 3d overdue |
| 18548348 | BENZOXAZOLONE INHIBITORS OF INFLAMMASOMES | HEASLEY, MEGHAN CHRISTINE | 27d |
| 18301093 | Human Adipose-Derived Stem Cell Exosomes And Their Packaging For Use At Room Temperature | CONNORS, ALEXANDRA F | 29d |
| 18478342 | SYSTEMS AND METHODS FOR HISTOTRIPSY IMMUNOSENSITIZATION | DEUTSCH, TAYLOR M | 40d |
| 18015169 | BIOFLUID-BASED PROTEIN AND MIRNA BIOMARKERS FOR NEONATAL HYPOXIC-ISCHEMIC ENCEPHALOPATHY | MCCOLLUM, ANDREA K | 60d |
| 19129959 | CATHETER AND METHODS OF USING SAME | LOUIS, RICHARD G | — |
| 18852356 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF STROKE | RAGHU, GANAPATHIRAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18702962 | ACTIVE PRESSURE RELIEVING SYSTEM | GREEN, RICHARD R | 66d overdue |
| 18548348 | BENZOXAZOLONE INHIBITORS OF INFLAMMASOMES | HEASLEY, MEGHAN CHRISTINE | 27d |
| 19129959 | CATHETER AND METHODS OF USING SAME | LOUIS, RICHARD G | — |
| 18979814 | Methods And Kits For Assessing Central Nervous System Integrity | CERIONI, DANIEL LEE | — |
| 18852356 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF STROKE | RAGHU, GANAPATHIRAM | — |
| 18812628 | METHODS AND KITS FOR DIAGNOSING, ASSESSING OR QUANTITATING DRUG USE, DRUG ABUSE AND NARCOSIS, INTERNUCLEAR OPHTHALMOPLEGIA, ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD), CHRONIC TRAUMATICENCEPH ALOPATHY,SCHIZOPHRENIA SPECTRUM DISORDERS AND ALCOHOL CONSUMPTION | GEBREMICHAEL, BRUK A | — |
| 18834436 | A MECHANO-RESPONSIVE NANOFIBROUS PATCH FOR THE DELIVERY OF BIOLOGICS IN LOAD-BEARING TISSUES | BAZARGANI, ARYA AHMADI | — |
| 18775053 | Diagnosis and Treatment of Metabolic Syndrome with Magnesium Compositions | PIPIC, ALMA | — |
| Art Unit | Apps |
|---|---|
| 1626 | 3 |
| 3771 | 2 |
| 1638 | 2 |
| 1622 | 2 |
| 1624 | 2 |
| 1628 | 2 |
| 3715 | 1 |
| 1613 | 1 |
| 1617 | 1 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19129959 | CATHETER AND METHODS OF USING SAME | LOUIS, RICHARD G | 3771 | §102§103 | Non-Final OA | — | Pending | May 14, 2025 |
| 18979814 | Methods And Kits For Assessing Central Nervous System Integrity | CERIONI, DANIEL LEE | — | DP | Non-Final OA | — | Pending | Dec 13, 2024 |
| 18852356 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF STROKE | RAGHU, GANAPATHIRAM | — | §102§103§112 | Non-Final OA | — | Pending | Sep 27, 2024 |
| 18812628 | METHODS AND KITS FOR DIAGNOSING, ASSESSING OR QUANTITATING DRUG USE, DRUG ABUSE AND NARCOSIS, INTERNUCLEAR OPHTHALMOPLEGIA, ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD), CHRONIC TRAUMATICENCEPH ALOPATHY,SCHIZOPHRENIA SPECTRUM DISORDERS AND ALCOHOL CONSUMPTION | GEBREMICHAEL, BRUK A | 3715 | DP | Final Rejection | — | Pending | Aug 22, 2024 |
| 18834436 | A MECHANO-RESPONSIVE NANOFIBROUS PATCH FOR THE DELIVERY OF BIOLOGICS IN LOAD-BEARING TISSUES | BAZARGANI, ARYA AHMADI | 1613 | §103 | Non-Final OA | — | Pending | Jul 30, 2024 |
| 18775053 | Diagnosis and Treatment of Metabolic Syndrome with Magnesium Compositions | PIPIC, ALMA | 1617 | §102§103§112 | Non-Final OA | — | Pending | Jul 17, 2024 |
| 18671007 | Non-Toxin Antigens For Clostridioides Difficile Vaccine | GRASER, JENNIFER E | 1645 | §101§102§112 | Non-Final OA | — | Pending | May 22, 2024 |
| 18710037 | METHOD OF TREATING CANCER ASSOCIATED WITH RAS MUTATION | BRAUN, MADELINE E | — | §102§103§112Other | Non-Final OA | — | Pending | May 14, 2024 |
| 18702962 | ACTIVE PRESSURE RELIEVING SYSTEM | GREEN, RICHARD R | 3647 | §103 | Non-Final OA | 66d overdue | Pending | Apr 19, 2024 |
| 18684563 | TREATMENT COMPOSITIONS AND METHODS | HEASLEY, MEGHAN CHRISTINE | 1626 | §102§103§112 | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18294467 | NERVE COUPLER AND METHOD FOR USE OF THE SAME | ADAM, MOHAMMED SOHAIL | 3771 | §103§112 | Non-Final OA | — | Pending | Feb 01, 2024 |
| 18417617 | COMPOSITIONS AND METHODS FOR SPATIAL AND TEMPORAL CONTROL OF NEUROTROPHIC GROWTH FACTOR EXPRESSION | AMICK, THOMAS RUSSE | 1638 | §102§103 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18390242 | COMPOSITIONS AND METHOD FOR TREATING GUT PERMEABILITY CAUSED BY HYDROGEN SULFIDE PRODUCING BACTERIA | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §103§112 | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18533784 | COMPOSITIONS AND METHODS FOR TREATING RIGHT VENTRICLE DYSFUNCTION | ZARA, JANE J | 4100 | §103 | Non-Final OA | — | Pending | Dec 08, 2023 |
| 18555169 | ERYTHROPOIETIN-DERIVED PEPTIDES FOR TREATING RELAPSING-REMITTING MULTIPLE SCLEROSIS | KOMATSU, LI N | 1658 | §102§112DP | Non-Final OA | — | Pending | Oct 12, 2023 |
| 18478342 | SYSTEMS AND METHODS FOR HISTOTRIPSY IMMUNOSENSITIZATION | DEUTSCH, TAYLOR M | 3798 | §102§103 | Final Rejection | 40d | Pending | Sep 29, 2023 |
| 18372662 | MUSCARINIC M2 RECEPTOR BLOCKADE TO DELAY OR PREVENT ONSET OF PROGRESSIVE MEMORY DECLINE | BORALSKY, LUKE ALAN | 1624 | §103§112DP | Non-Final OA | — | Pending | Sep 25, 2023 |
| 18548348 | BENZOXAZOLONE INHIBITORS OF INFLAMMASOMES | HEASLEY, MEGHAN CHRISTINE | 1626 | §103§112 | Non-Final OA | 27d | Pending | Aug 30, 2023 |
| 18274293 | COMPOSITIONS AND METHODS FOR INHIBITING YAP | COUGHLIN, MATTHEW P | 1626 | §102§103§112 | Non-Final OA | — | Pending | Jul 26, 2023 |
| 18271618 | METHOD OF GENE DELIVERY TO RETINAL ASTROCYTES | BRETZ, COREY LANE | 1635 | §103§112 | Final Rejection | 3d overdue | Pending | Jul 10, 2023 |
| 18301093 | Human Adipose-Derived Stem Cell Exosomes And Their Packaging For Use At Room Temperature | CONNORS, ALEXANDRA F | 1634 | §102§103§112 | Non-Final OA | 29d | Pending | Apr 14, 2023 |
| 18043163 | HYDROXYNORKETAMINE COMPOUNDS AND METHODS OF USE THEREOF | RAO, PADMAJA S | 1627 | §102§103§112 | Non-Final OA | — | Pending | Feb 27, 2023 |
| 18164699 | NOVEL EFFICACIOUS MICRORNA-30C ANALOGS REDUCE APOLIPOPROTEIN B SECRETION IN HUMAN LIVER CELLS | CHONG, KIMBERLY | 1636 | §103 | Final Rejection | — | Pending | Feb 06, 2023 |
| 18015169 | BIOFLUID-BASED PROTEIN AND MIRNA BIOMARKERS FOR NEONATAL HYPOXIC-ISCHEMIC ENCEPHALOPATHY | MCCOLLUM, ANDREA K | 1674 | §101§102§112 | Non-Final OA | 60d | Pending | Jan 09, 2023 |
| 18008605 | USE OF OXYGENATED CHOLESTEROL SULFATES FOR TREATING INFLAMMATORY CONDITIONS | RODRIGUEZ, RAYNA B | 1628 | §103§112 | Non-Final OA | 66d overdue | Pending | Dec 06, 2022 |
| 17925775 | Methods and Compositions for Treating Pain While Minimizing the Risk of Opioid Addiction | SOROUSH, LAYLA | 1622 | §103 | Non-Final OA | 35d overdue | Pending | Nov 16, 2022 |
| 17980164 | MEDICAL TREATMENTS BY COGNITIVE DISCONNECTION | HONRATH, MARC D | 3791 | §102§112 | Non-Final OA | — | Pending | Nov 03, 2022 |
| 17800208 | EGFR INHIBITION TRIGGERS AN ADAPTIVE RESPONSE BY CO-OPTING ANTIVIRAL SIGNALING PATHWAYS IN LUNG CANCER | LEE, CHIHYI NMN | 1628 | §103§112 | Non-Final OA | — | Pending | Aug 16, 2022 |
| 17842225 | METHODS FOR TREATING EYE DISEASE | VIVLEMORE, TRACY ANN | 1638 | §103 | Final Rejection | 28d overdue | Pending | Jun 16, 2022 |
| 17767709 | RAPID MANUFACTURING OF ABSORBENT SUBSTRATES FOR SOFT, CONFORMABLE SENSORS AND CONDUCTORS | LEE, DAVINA EN-YIN | 3794 | §103 | Non-Final OA | — | Pending | Apr 08, 2022 |
| 17625059 | TREATMENT OF PULMONARY FIBROSIS USING INHIBITORS OF NEU1 SIALIDASE | COLEMAN, BRENDA LIBBY | 1624 | §102 | Non-Final OA | — | Pending | Jan 05, 2022 |
| 17609757 | COMPOSITIONS AND METHODS FOR TREATING CANCER | HADDAD, MAHER M | 1641 | §103 | Non-Final OA | — | Pending | Nov 08, 2021 |
| 17276213 | VECTORS EXPRESSING COLOR AND SELECTABLE MARKERS | SPENCE, JENNIFER SUZANNE | 1633 | §103 | Final Rejection | 30d overdue | Pending | Mar 15, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial